

ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19

B. SANCHEZ RODRIGUEZ¹, R. GAZQUEZ PEREZ¹, M.T. GOMEZ SÁNCHEZ¹, D. GAMEZ TORRES¹, M. SÁNCHEZ VALERA¹, T. MORENO DIAZ¹
¹H.U TORRECÁRDENAS, PHARMACY, ALMERIA, SPAIN.

BACKGROUND AND IMPORTANCE


- **Sotrovimab** is indicated in **treatment of COVID19** in **adults and adolescents** who do **not require supplemental oxygen** and who are at **increased risk** of progressing to **COVID-severe**.
- The drug is **administered** according to **prioritization criteria** published by the Spanish Agency of Medicines and Health Products (**AEMPS**)

AIM AND OBJETIVES

To analyze the effectiveness of sotrovimab and to know the profile of patients

MATERIAL AND METHODS

Observational, retrospective and **descriptive** study in a tertiary level hospital. Patients who had received sotrovimab from January/2022-May/2022. Effectiveness was measured as rate of patients without progression to COVID-severe (defined as hospitalization/death at 29 days)



RESULTS

-**37 patients** were included, mean age= **61 years** (21-82), **20 women** (54.05%).



-**29 (78.38%)** had **mild-moderate COVID**.

According to the AEMPS prioritization criteria, all belonged to the group of "Immunocompromised persons and high-risk conditions, regardless of vaccination status" :

-**7 patients (18.9%)** were **hospitalized/dead at 29 days (3 exitus)**. All these patients had received **rituximab**.

-**30 patients (81.1%)** did **not progress to severe COVID**.


-**6 patients** attended the **emergency department, without admission**.



All immunosuppressed...

And the high-risk conditions:

- ✓ 23 patients (62.16%) solid organ transplantation with immunosuppressive treatment
- ✓ 13 patients (35.14%) immunosuppressive treatment with antiCD20 (100% rituximab)
- ✓ 1 patient (2.7%) treatment with myelotoxic chemotherapy (inotuzumab)



CONCLUSION AND RELEVANCE

Most patients presented **good response** and **tolerance** to treatment. This result was **independent of previous treatments or risk factors**. Previous treatment with anti-CD20 seems to show a tendency to progression to severe COVID. Long-term studies are needed to confirm results

